|Articles|February 17, 2018

Evidence-Based Oncology

  • February 2018
  • Volume 24
  • Issue 2

eAppendix

References for: Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Download PDF: eAppendix

Articles in this issue

almost 8 years ago

Medical World News: Clinical/Managed Care Updates

almost 8 years ago

Medical World News: Clinical Updates

almost 8 years ago

Medical World News: Regulatory Updates

almost 8 years ago

Future Shock: Embracing Disruption in the Immunotherapy Revolution

almost 8 years ago

With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage

almost 8 years ago

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

almost 8 years ago

Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry

almost 8 years ago

The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"

almost 8 years ago

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text